Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
valsartan + enalapril
- Development stage
- Phase 3
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Valsartan + enalapril is a combination of two antihypertensive agents used to manage high blood pressure and heart failure. Valsartan is an angiotensin II receptor blocker (ARB) that works by blocking the action of angiotensin II, leading to vasodilation and reduced blood pressure. Enalapril is a prodrug that, after conversion to its active form enalaprilat, inhibits angiotensin-converting enzyme (ACE), thereby reducing the production of angiotensin II and aldosterone secretion. Both drugs act on different points in the renin-angiotensin-aldosterone system but should generally not be combined due to increased risk of adverse effects such as hyperkalemia, kidney impairment, and hypotension[1][2][3][5][6][8].
02
Targets
AGTR1 (Angiotensin II Type-1 receptor)ACE (Angiotensin Converting Enzyme)
Beyond the preview
Go deeper on valsartan + enalapril.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on valsartan + enalapril.